Online inquiry

IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7933MR)

This product GTTS-WQ7933MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ICOS gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_012092.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29851
UniProt ID Q9Y6W8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7933MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11197MR IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-1873
GTTS-WQ11781MR IVTScrip™ mRNA-Anti-IL23A, MK-3222(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MK-3222
GTTS-WQ13126MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PF-04360365
GTTS-WQ12604MR IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA NVS250519
GTTS-WQ9013MR IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IMC RON-8
GTTS-WQ11509MR IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MFGR1877S
GTTS-WQ13286MR IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PF-06523435
GTTS-WQ114MR IVTScrip™ mRNA-Anti-EGFR, 11F8(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 11F8
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW